Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2010 4
2011 1
2012 2
2013 4
2015 4
2016 7
2017 9
2018 5
2019 9
2020 6
2021 5
2022 8
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D, Russo A, Gunasekaran M, Buemi F, Hester L, Fan X, Carter-Cooper BA, Lapidus RG, Peleg A, Arroyo-Hernández M, Cardona AF, Naing A, Hirsch FR, Mack PC, Kaushal S, Serrano MJ, Adamo V, Arrieta O, Rolfo C. de Miguel-Perez D, et al. Among authors: lapidus rg. Cancer. 2023 Feb 15;129(4):521-530. doi: 10.1002/cncr.34576. Epub 2022 Dec 9. Cancer. 2023. PMID: 36484171 Free article.
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.
Duru N, Pawar NR, Martin EW, Buzza MS, Conway GD, Lapidus RG, Liu S, Reader J, Rao GG, Roque DM, Leppla SH, Antalis TM. Duru N, et al. Among authors: lapidus rg. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2201423119. doi: 10.1073/pnas.2201423119. Epub 2022 Jul 8. Proc Natl Acad Sci U S A. 2022. PMID: 35867758 Free PMC article.
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. de Miguel-Perez D, et al. Among authors: lapidus rg. J Exp Clin Cancer Res. 2022 Jun 2;41(1):186. doi: 10.1186/s13046-022-02379-1. J Exp Clin Cancer Res. 2022. PMID: 35650597 Free PMC article.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: lapidus rg. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
58 results